People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is planned to last about 12 months for each person. It compares the two inhaled medicines in a random way, and the treatment is given through an inhaler. During the study, asthma symptoms and general control of asthma are checked at several visits, and the treatment is continued while these checks are done. The main purpose of the study is to see whether Trimbow works at least as well as Fostair for asthma control.

The study also looks at how often people have worse asthma attacks, how often they need steroid tablets by mouth, and whether breathing and quality of life change during the study. Safety is also watched throughout the treatment period.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The study is designed for adults with newly diagnosed, low-risk disease. Treatment is given in phases over time, including an early treatment period and later treatment cycles called consolidation, which are used to help keep the disease under control after the first response. During the study, blood tests, heart checks, and other routine medical checks are done, and side effects are watched closely. The study also looks at how the body handles QTX-2101 and whether the leukemia goes away to a very deep level, meaning no clear signs of the cancer marker PML/RARA can be found in the bone marrow.

The purpose of the study is to evaluate the long‑term safety and tolerability of the medication. Over several months, participants will take the drug each day and attend regular clinic visits where doctors will check blood work (laboratory tests that look at how the body is functioning), perform an ECG (a quick test that records the heart’s electrical activity), measure vital signs such as blood pressure and weight, and conduct simple memory and thinking assessments to see how cognition changes.

Throughout the trial, any side effects or new health problems will be recorded, and participants may stop the medication if serious issues arise. The overall goal is to determine whether the drug can be used safely for people living with this condition.

The study lasts about 72 weeks. People in the study are placed into different groups by chance, and neither the participants nor the study team know who receives RO7795068 or placebo during the study. Before treatment starts, a first check is done. After that, the medicine is given regularly, and follow-up visits continue through the study period to monitor weight, blood sugar, and overall health.

The study also looks at changes related to HbA1c, a blood test that shows average blood sugar over time, as well as waist size, blood pressure, cholesterol, and possible side effects. It also checks how the treatment may affect daily physical function and quality of life.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

Participants in this study must have been diagnosed with Type 1 Diabetes within 8 weeks before starting the study medication. They must also have certain antibodies in their blood that are related to Type 1 Diabetes, such as antibodies against glutamic acid decarboxylase, insulinoma antigen-2, zinc-transporter 8, insulin, or islet cell cytoplasmic autoantibodies. Antibodies are proteins made by the immune system that can sometimes attack the body’s own tissues. The study will also measure C-peptide, which is a substance that shows how much insulin the body is still making on its own. Participants need to have a certain level of C-peptide to be eligible for the study.

During the study, doctors will check several things to see how well the treatment is working. They will measure glycated hemoglobin, also called HbA1c, which shows average blood sugar levels over time. They will count how many days participants can go without needing insulin at mealtimes. They will also use a mixed meal tolerance test to measure C-peptide levels after participants eat a standard meal. The study will use continuous glucose monitoring to track blood sugar levels throughout the day and night. Doctors will watch for low blood sugar events, which are called hypoglycemic events, and will check for any side effects or unwanted reactions to the medication. They will also measure the amount of teplizumab in the blood and check if the body develops antidrug-antibodies, which are immune responses against the medication.

The purpose of this study is to see if NBI-1117568 works better than placebo at improving the behavioral and psychological symptoms of schizophrenia in adults. The study will look at whether the medication can help reduce symptoms and improve the overall condition of people who are experiencing a sudden worsening of their schizophrenia symptoms that requires them to stay in the hospital. The study will also check how safe the medication is and whether people can tolerate it well.

People taking part in this study will be adults with schizophrenia who are currently in the hospital because their symptoms have gotten worse recently. The study will last for 5 weeks, during which time participants will take either NBI-1117568 or placebo capsules. Throughout the study, doctors will measure changes in symptoms using rating scales to see how well the treatment is working compared to placebo.

The purpose of the study is to see if ziltivekimab works better than placebo in reducing the risk of serious heart-related problems in people who have both cardiovascular disease and kidney disease along with signs of inflammation in their body. The main focus is on preventing major cardiovascular events, which include death from heart-related causes, non-fatal heart attack, and non-fatal stroke. A heart attack occurs when blood flow to part of the heart muscle is blocked, while a stroke happens when blood flow to part of the brain is interrupted.

During the study, participants will receive either ziltivekimab or placebo through regular injections while continuing their standard medical treatment. The study will track various health outcomes over time, including heart attacks, strokes, heart-related deaths, hospital admissions for heart problems, and changes in kidney function. Researchers will also monitor changes in inflammation markers in the blood, heart function measurements, and overall health status. The study will measure how the kidneys are working by looking at blood test results that show the filtering ability of the kidneys and the amount of protein in the urine, which can indicate kidney damage.

The medications being tested contain active substances called trospium chloride and xanomeline tartrate. They come in the form of capsules that are taken by mouth. The study will involve patients who have previously participated in related research studies of these medications.

During the study, researchers will monitor various aspects of participants’ health, including any side effects, changes in body weight, blood pressure, heart rate, and mental function. They will also check for any unusual movements, restlessness, and other health-related factors to ensure the medications’ safety over extended use.

The purpose of the study is to compare the effectiveness of a new medicine with that of standard chemotherapy. The investigational drug being tested is Sofetabart Mipitecan (LY4170156). For participants with platinum-resistant disease, the new drug may be given alone and compared with the doctor’s choice of chemotherapy drugs such as carboplatin, paclitaxel, gemcitabine, topotecan or doxorubicin, or with Mirvetuximab Soravtansine. For those with platinum-sensitive disease, the new drug is combined with bevacizumab and compared with a standard platinum‑based two‑drug chemotherapy regimen plus bevacizumab.

Participants receive the study medicines through an IV infusion every few weeks and attend regular clinic visits where doctors perform physical examinations and imaging scans to check how the cancer is responding. Treatment continues until the cancer grows, side effects become unacceptable, or the study period ends, which may be several months for each participant.

Participants in the study will receive either the BIIB059 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the activity of their lupus. The goal is to see if BIIB059 can reduce the symptoms and activity of lupus more effectively than the placebo.

Throughout the study, various aspects of the participants’ health will be assessed, including their response to the treatment and any changes in their lupus symptoms. The study will also track any side effects or adverse events that may occur. This research is important for understanding whether BIIB059 can be a beneficial treatment option for people living with systemic lupus erythematosus.

The purpose of the study is to determine how well lumateperone works in reducing the symptoms of mania over a period of three weeks. During this time, participants will take the medication daily and will be monitored by healthcare professionals. The study will compare the changes in symptoms from the beginning to the end of the three-week period to assess the medication’s impact.

Participants in the study will be randomly assigned to receive either the new medication, the placebo, or Deucravacitinib. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will take place over several weeks, during which participants will take the medication orally and attend regular check-ups to monitor their progress and any side effects.

The goal is to determine if JNJ-77242113 can improve the symptoms of plaque psoriasis more effectively than the placebo or Deucravacitinib. Participants will be monitored for changes in their skin condition and overall health. The study aims to provide valuable information that could lead to new treatment options for people living with moderate to severe plaque psoriasis.

The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect. The goal is to see if Bepirovirsen can help reduce the virus to very low levels or eliminate it altogether, allowing participants to stop their current hepatitis B treatment.

Throughout the study, participants will be closely monitored to ensure their safety and to assess how well the treatment is working. The study aims to provide valuable information on whether Bepirovirsen can be an effective treatment option for people with chronic hepatitis B, potentially leading to a new way to manage this condition.

Participants will be assigned to receive either clemizole hydrochloride in the form of an oral solution or a placebo. The study is designed as a double-blind trial, meaning that neither the participants nor the researchers will know which substance is being administered during the process. The course of the study involves different stages, including a period where the dose is gradually adjusted, followed by a maintenance period where the treatment is continued.

Participants in this research will be randomly assigned to receive either REGN7508 or a placebo. This is a double-blind study, meaning that neither the participants nor the researchers know which treatment is being administered. During the course of the study, the effectiveness of the medication in preventing blood clots and its impact on the risk of bleeding will be monitored. This includes looking for any significant bleeding events to ensure the safety of the treatment.

The study has two parts. In Part A, healthy volunteers will receive a single dose of GS-4321 given either as an injection under the skin or into a vein. This part will help researchers understand how the medication moves through the body and whether it causes any unwanted effects. In Part B, people who have chronic hepatitis delta infection will receive multiple doses of GS-4321 over time. These participants must already be taking certain medications for hepatitis B, such as entecavir, tenofovir alafenamide, or tenofovir disoproxil fumarate. Researchers will check the virus levels in the blood and monitor liver function through blood tests and measurements of liver stiffness using a special imaging method called elastography.

Throughout the study, participants will have regular visits where blood samples will be taken to measure virus levels, check how the liver is working, and look for any side effects. The study will also check whether participants develop immune responses to the medication by looking for antidrug antibodies in the blood. For those in Part B, the treatment period will last up to 96 weeks, with regular monitoring to see how well the medication works in reducing virus levels and improving liver health markers such as alanine aminotransferase, which is a substance in the blood that can indicate liver inflammation.

The purpose of this study is to find out if adding Revumenib to intensive chemotherapy helps people with this type of leukemia live longer without their disease getting worse compared to chemotherapy alone, and to see if this combination helps more people achieve complete remission with no detectable signs of cancer cells remaining in their bone marrow. During the study, participants will receive their assigned treatment and will be monitored regularly to check how well the treatment is working and to watch for any side effects. The study will track various outcomes including how long participants live, how long they remain in remission, and how many participants achieve complete remission with no measurable remaining disease.

The study will also carefully monitor the safety of the treatment by recording any unwanted effects that occur, checking blood test results regularly, and performing heart function tests and other examinations. Doctors will measure treatment success by looking at whether the cancer goes away completely, whether cancer cells can still be detected in the bone marrow or blood using special tests, and how long participants remain free of cancer. The study is expected to continue for several years to gather enough information about the long-term effects of this treatment combination.

The study will compare two different doses of vipoglanstat with placebo to see which works best. Participants will take the medication by mouth in capsule form. During the study, women will be asked to record their pain levels, particularly focusing on pain during days when they are not menstruating. The study will also look at pain during menstrual bleeding days, which is called dysmenorrhea. Information will be collected about any use of pain relief medications, including opioid medications, which are strong pain relievers. The study will also measure how endometriosis affects quality of life and daily activities using questionnaires.

The treatment period will last for four months, during which participants will attend several visits. Throughout the study, doctors will monitor participants for any side effects and will perform regular safety checks including blood tests and urine tests. The study will track changes in pain levels from the beginning of treatment to the end of the four-month period to determine if vipoglanstat is effective in reducing endometriosis-related pain.

The purpose of the study is to compare how well BGB-16673 works against pirtobrutinib in controlling the disease and to evaluate the safety of both treatments. The study will measure how long patients live without their disease getting worse, which is called progression-free survival. This will be assessed by an independent group of medical experts who will review imaging scans and other test results. The study will also look at overall survival, which means how long patients live overall, and will measure how many patients respond to treatment by having their disease shrink or disappear. Additional measurements include how long the treatment response lasts and how long it takes before patients need another treatment for their disease.

During the study, patients will be randomly assigned to receive either BGB-16673 or pirtobrutinib. Both groups will continue taking their assigned medication for up to 42 months unless their disease gets worse or they experience unacceptable side effects. The study will monitor patients for any unwanted effects of the medications and will track how severe these effects are. Patients will also complete questionnaires about their quality of life, including questions about their physical functioning, symptoms, and overall health status. The study will use computed tomography or magnetic resonance imaging scans to measure disease in patients with small lymphocytic lymphoma, looking for lymph nodes that are larger than normal size.

During the study, participants will be randomly assigned to receive either ML-007C-MA or placebo for a treatment period of seven weeks. The maximum daily dose of ML-007C-MA that may be given is 210 milligrams. Participants will need to have a care partner who can provide information about their symptoms and help them follow the study requirements. The care partner must be in regular contact with the participant and will need to attend all study visits with them. Participants must have been living in the same home or care facility for at least six weeks before joining the study and are expected to stay there throughout the study period.

Throughout the study, doctors will measure changes in hallucinations and delusions using rating scales that assess the severity of these symptoms. They will compare scores from the beginning of the study to scores after seven weeks of treatment. The study will also look at whether the treatment helps with other symptoms such as agitation and aggression in some participants, and will measure how much distress caregivers experience related to the participant’s hallucinations and delusions. Participants must be between 55 and 90 years old and meet specific criteria related to their Alzheimer’s disease diagnosis and the presence of psychotic symptoms for at least two months. A brain scan using MRI or CT must be available or completed during the screening period.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study will compare these medications to placebo to see if they can help reduce agitation symptoms in people with Alzheimer’s Disease. During the study, participants will be randomly assigned to receive either the study medications or placebo. Neither the participants nor their doctors will know which treatment they are receiving.

The main way of measuring if the treatment works will be through a special rating scale that measures agitation behaviors. Throughout the study, participants will need to have a caregiver who spends at least 10 hours per week with them to help monitor their condition and assist with taking the medication correctly.